Crispr Therapeutics Ag (CRSP)

$60.48

-2.27

(-3.62%)

Market is closed - opens 7 PM, 18 Jul 2024

Performance

  • $60.26
    $63.34
    $60.48
    downward going graph

    0.36%

    Downside

    Day's Volatility :4.86%

    Upside

    4.51%

    downward going graph
  • $37.55
    $91.10
    $60.48
    downward going graph

    37.91%

    Downside

    52 Weeks Volatility :58.78%

    Upside

    33.61%

    downward going graph

Returns

PeriodCrispr Therapeutics AgSector (Health Care)Index (Russel 2000)
3 Months
12.94%
8.2%
0.0%
6 Months
3.11%
7.5%
0.0%
1 Year
7.78%
14.3%
0.0%
3 Years
-50.09%
16.5%
-18.2%

Highlights

Market Capitalization
5.2B
Book Value
$24.56
Earnings Per Share (EPS)
-2.7
PEG Ratio
-0.21
Wall Street Target Price
84.29
Profit Margin
-79.92%
Operating Margin TTM
-27894.25%
Return On Assets TTM
-7.97%
Return On Equity TTM
-11.02%
Revenue TTM
271.7M
Revenue Per Share TTM
3.4
Quarterly Revenue Growth YOY
-99.5%
Gross Profit TTM
-570.7M
EBITDA
-279.0M
Diluted Eps TTM
-2.7
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-5.63
EPS Estimate Next Year
-4.53
EPS Estimate Current Quarter
-1.33
EPS Estimate Next Quarter
-1.58

Analyst Recommendation

Buy
    54%Buy
    37%Hold
    8%Sell
Based on 35 Wall street analysts offering stock ratings for Crispr Therapeutics Ag(by analysts ranked 0 to 5 stars)
Based on 35 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
19
19
19
Hold
13
13
12
Sell
3
3
3

Analyst Forecast

What analysts predicted

Upside of 39.37%

Current $60.48
Target $84.29

Technicals Summary

Sell

Neutral

Buy

Crispr Therapeutics Ag is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Crispr Therapeutics Ag
Crispr Therapeutics Ag
1.56%
3.11%
7.78%
-50.09%
27.44%
Moderna, Inc.
Moderna, Inc.
-9.25%
24.7%
2.07%
-60.09%
791.95%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
4.75%
17.85%
51.74%
87.1%
265.7%
Novo Nordisk A/s
Novo Nordisk A/s
0.36%
32.05%
75.05%
218.96%
483.19%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.23%
12.73%
36.59%
145.42%
176.04%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Crispr Therapeutics Ag
Crispr Therapeutics Ag
13.4
NA
-0.21
-5.63
-0.11
-0.08
NA
24.56
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.18
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.94
31.94
1.46
44.22
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
48.76
48.76
2.36
3.45
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.85
31.85
0.53
17.07
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Crispr Therapeutics Ag
Crispr Therapeutics Ag
Buy
$5.2B
27.44%
13.4
-79.92%
Moderna, Inc.
Moderna, Inc.
Buy
$48.0B
791.95%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$119.2B
265.7%
31.94
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$633.1B
483.19%
48.76
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.7B
176.04%
31.85
39.46%

Insights on Crispr Therapeutics Ag

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 200.0M → 504.0K (in $), with an average decrease of 99.8% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 89.34M → -116.59M (in $), with an average decrease of 230.5% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 75.0% return, outperforming this stock by 67.2%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 217.8% return, outperforming this stock by 268.1%

Institutional Holdings

  • ARK Investment Management LLC

    9.61%
  • Capital Research & Mgmt Co - Division 3

    9.23%
  • Sumitomo Mitsui Trust Holdings Inc

    3.85%
  • Nikko Asset Management Americas Inc

    3.85%
  • T. Rowe Price Investment Management,Inc.

    3.18%
  • BlackRock Inc

    3.00%

Company Information

CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Organization
Crispr Therapeutics Ag
Employees
407
CEO
Dr. Samarth Kulkarni Ph.D.
Industry
Health Technology

FAQs